Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Foradil, Forair, Formoterol, Novolizer Formoterol, Oxis; Belgium: Foradil, Novolizer Formoterol, Oxis; Bulgaria: Atimos, Foradil; Cyprus: Broncoteril, Foradil; Denmark: Delnil, Eformax, Foradil, Foraform, Oxis; Estonia: Atimos, Diffumax, Foradil, Licaformot, Oxis; Finland: Cycloterol, Fomeda, Foradil, Formaxa, Formoterol, Oxis; France: Asmelor, Foradil, Formoair; Germany: Atifor, Foradil, Forair, Formatris, FormoLich, Formoterol, Formotop, Oxis; Greece: Atifor, Broncoteril, Efuril, Forair, Forcap, Formaxa, Formopen, Imotec, Kinitron; Hungary: Atimos, Chemoterol, Diffumax, Foradil, Forair, Oxis; Ireland: Foradil, Formoterol, Novolizer Formoterol, Oxis; Italy: Aliterol, Atimos, Eolus, Evervent, Feronal, Foradil, Formoterolo, Forotan, Fortasint, Kurovent, Levovent, Liferol, Oxis; Latvia: Atimos, Diffumax, Foradil, Licaformot, Oxis; Lithuania: Atimos, Diffumax, Foradil, Licaformot, Oxis; Malta: Atimos, Foradil, Oxis; Netherlands: Atimos, Foradil, Formoterol, Oxis; Poland: Atimos, Diffumax, Foradil, Foramed, Forastmin, Oxis, Oxodil, Zafiron; Portugal: Asmatec, Atimos, Foradil, Forair, Formaxa, Formoterol, Oxis; Romania: Atimos, Pneumera; Slovakia: Atimos, Foradil, Formano, Formoterol, Formovent, Forair, Oxis; Slovenia: Atimos, Oxis; Spain: Broncoral, Foradil, Formatris, Formoterol, Neblik, Oxis; Sweden: Foradil, Formatris, Formoterol, Oxis; UK: Atimos, Foradil, Formoterol, Oxis.

North America

Canada: Foradil, Oxeze; USA: Foradil, Perforomist.

Latin America

Argentina: Oxis, Xanol; Brazil: Fluir, Foradil, Formare, Formocaps, Oxis; Mexico: Foradil.


Japan: Atock.

Drug combinations

Formoterol and Beclomethasone

Formoterol and Budesonide

Formoterol and Mometasone


Formoterol Fumarate: (C~19~H~24~N~2~O~4~)~2~ C~4~H~4~O~4~. Mw: 804.88. (±)-2′-Hydroxy-5′-[(R*)-1-hydroxy-2-[[(R*)-p-methoxy-α-methylphenethyl]amino]ethyl]formanilide fumarate (2:1). CAS-43229-80-7; CAS-73573-87-2 (formoterol).(1997).

Pharmacologic Category

Sympathomimetic (Adrenergic) Agents; Selective β~2~-Adrenergic Agonists. (ATC-Code: R03AC13).

Mechanism of action

Relaxes bronchial smooth muscle by selective action on β~2~-receptors with little effect on heart rate.

Therapeutic use

Maintenance treatment of asthma and prevention of bronchospasm in patients ≥5 years of age with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. Maintenance treatment of bronchoconstriction in COPD. Prevention of exercise-induced bronchospasm in patients ≥5 years of age.

Pregnancy and lactiation implications

There are no adequate, well-controlled studies in pregnant women. β-Agonists interfere with uterine contractility so use during labor only if benefit outweighs risk to fetus.

Unlabeled use


Hypersensitivity to formoterol, inhaled lactose, or any component of the formulation. Presence of tachyarrhythmias.

Warnings and precautions

Long-acting β~2~-agonists may increase risk of asthma-related deaths. Risk may be greater in African-American patients vs Caucasians. Rarely, paradoxical bronchospasm might occur with use of inhaled bronchodilating agents. Immediate hypersensitivity reactions (angioedema, bronchospasm, rash, urticaria) reported. Serious effects/fatalities associated with excessive use of inhaled sympathomimetics. Use with caution in cardiovascular disease (arrhythmia, coronary insufficiency, hypertension, or HF), since β-agonists may cause elevation in blood pressure and heart rate and result in CNS stimulation/excitation. β~2~-Agonists may also increase risk of arrhythmias and prolong QTc interval. Formoterol should not be used for treatment of rapidly deteriorating, or acute symptomatic COPD. Use with caution in diabetes mellitus (β~2~-agonists may increase serum glucose), glaucoma (may elevate intraocular pressure), hyperthyroidism (may stimulate thyroid activity), hypokalemia (β~2~-agonists may decrease serum potassium), seizure disorders (β-agonists may result in CNS stimulation/excitation). Powder for oral inhalation contains lactose (caution with severe milk protein allergy).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart